Lysophosphatidic acid (LPA) is a metabolically labile natural phospholipid with a bewildering array of physiological effects. We describe herein a variety of long-lived receptor-specific agonists and antagonists for LPA receptors. Several LPA and PA (phosphatidic acid) analogues also inhibit LPP (lipid phosphate phosphatase). The sn-1 or sn-2 hydroxy groups have been replaced by fluorine, difluoromethyl, difluoroethyl, O-methyl or O-hydroxyethoxy groups to give non-migrating LPA analogues that resist acyltransferases. Alkyl ether replacement of acyl esters produced lipase and acyltransferase-resistant analogues. Replacement of the bridging oxygen in the monophosphate by an α-monofluoromethylene-, α-bromomethylene-or α,α-difluoromethylenephosphonate gave phosphatase-resistant analogues. Phosphorothioate analogues with O-acyl and O-alkyl chains are potent, long-lived agonists for LPA 1 and LPA 3 receptors. Most recently, we have (i) prepared stabilized O-alkyl analogues of lysobisphosphatidic acid, (ii) explored the structureactivity relationship of stabilized cyclic LPA analogues and (iii) synthesized neutral head group trifluoromethylsulphonamide analogues of LPA. Through collaborative studies, we have collected data for these stabilized analogues as selective LPA receptor (ant)agonists, LPP inhibitors, TREK (transmembrane calcium channel) K + channel agonists, activators of the nuclear transcription factor PPAR-γ (peroxisome-proliferatoractivated receptor-γ ), promoters of cell motility and survival, and radioprotectants for human B-cells.
Metabolically stabilized LPA and PA (phosphatidic acid) analogues: why and how?
As illustrated in Figure 1 , the catabolism of LPA proceeds via three main pathways [6] : (i) LPP (lipid phosphate phosphatase) enzymes hydrolyse the phosphomonoester to monoacylglycerol, (ii) acyltransferases [LPA acetyltransferases (LPAATs)] esterify LPA to PA and (iii) LPA-specific LPLs (lysophospholipases) hydrolyse the sn-1 acyl chain to form the corresponding glycerol phosphate. In addition, a non-enzymatic intramolecular acyl chain migration occurs, which results in the interconversion of the sn-1-and sn-2-acyl species [7] .
In order to identify receptor-selective LPA analogues and to document in detail the SARs (structure-activity relationships) of LPA isosteres, we survey herein a variety of LPA analogues in which labile groups have been chemically stabilized. For example, the phosphate head group was replaced with charged and neutral phosphomimetics [8] , the sn-1 and sn-2 hydroxy groups with fluorine [8] and methoxy or 2-He (2-hydroxyethoxy) [9] and the acyl esters with alkyl ethers [10] . The phosphomimetics include methylene (-CH 2 -) phosphonates, α-X methylene phosphonates (where X = -CHF-, CHBr-or -CHOH-), phosphorothioates, phosphonothioates, methyl phosphonates and monofluoromethyl phosphonates. In several studies of receptor activation, the activities of phosphomimetic LPA analogues are correlated with the second pK a values (Y. Xu, R. Tsukahara, G. Tigyi and G.D. Prestwich, unpublished work). There are three types of phosphomimetic functional groups that may display higher affinity for LPA receptors, either as agonists or antagonists: monofluoromethylenephosphonate, phosphonothioate and the phosphothioate. Importantly, two of these three phosphomimetics have the same value of second pK a as phosphate (Figure 2 ).
Synthesis and biological activity of LPA and PA analogues
In this section, we survey the synthetic approaches and biological activities of the stabilized LPA analogues. The goal is to present the scope of potential applications; additional details are available in the references cited.
Hydroxy to fluorine substitutions
An efficient route to enantiomerically homogeneous lysophospholipid analogues produced two 1,1-difluorodeoxy analogues of (2R)-acyl-sn-glycerol 3-phosphate [7] . By a separate route, two 3-difluoromethyl-substituted analogues of 1-acyl-sn-glycerol 3-phosphate were also prepared. All four compounds were migration-blocked analogues of the labile sn-2 LPA species. Using a nuclear reporter assay in which monocytic cells were transfected with a luciferase construct activated by a PPAR-γ nuclear receptor response element, the 3-difluoromethyl-substituted analogues were found to be as active as natural LPA [12] . However, these analogues showed little or no agonist activity towards the LPA-responsive GPCRs.
We then synthesized a series of monofluorinated LPA analogues in which either the sn-1 or sn-2 hydroxy group was replaced by fluorine, or the bridging oxygen in the monophosphate was replaced by an α-monofluoromethylene (-CHF-) moiety [13] . The sn-1 or sn-2 monofluorinated LPA analogues were enantiospecifically prepared from chiral-protected glycerol synthons, and the α-monofluoromethylene-substituted LPA analogues were prepared from a racemic epoxide using hydrolytic kinetic resolution. The sn-2 and sn-1 fluoro LPA analogues were unable to undergo acyl migration, effectively 'freezing' the acyl chain in the sn-1-or sn-2-position respectively.
We tested these LPA analogues on insect Sf9 cells that had been induced to express human LPA 1 , LPA 2 or LPA 3 receptors. While none of the analogues were found to be more potent than 1-oleoyl-LPA at LPA 1 and LPA 2 , several LPA analogues were potent LPA 3 -selective agonists. In contrast, 1-oleoyl-LPA had similar activity at all three receptors. analogue was also more effective than 1-oleoyl-LPA for the activation of MAPK (mitogen-activated protein kinase) and Akt in cells that expressed high levels of LPA 3 . The α-fluoromethylene phosphonate moiety increased the halflife of the analogue in cell culture from 30 min for LPA to 17 h for XY-17. Thus α-fluoromethylene LPA analogues are clearly unique new phosphatase-resistant ligands that provide enantiospecific and receptor-specific biological readouts [8] .
Hydroxy to HE substitutions
We developed an efficient enantioselective synthesis of HEsubstituted analogues of sn-1-acyl and -2-acyl LPA derivatives to eliminate the susceptibility of LPA to intramolecular acyl migration. While the palmitoyl HE-LPA analogues failed to activate calcium release in cells transfected with LPA 2 or LPA 3 , the LPA 3 receptor was activated by both 1-and 2-HE oleoyl LPA analogues with a potency 10-fold lower than the parent oleoyl LPA [9] .
Phosphonate analogues: the importance of α-substituents A versatile, efficient method for the preparation of α-monofluoromethylene (-CHF-) phosphonates from α-fluorovinylphosphonate provides access to a class of LPA receptorsubtype selective agonists. This method included a useful selective O-methylation reagent and the selective etherification of 1,2-diols to prepare to a new class of sn-1 O-methyl, 2-acyl α-monofluoromethylene LPA analogues [14] .
Substitution of the bridging oxygen in the monophosphate by an α-monofluoromethylene (-CHF-) moiety but not by α,α-difluoromethylene (-CF 2 -) resulted in a potent and selective agonist for LPA 3 . Originally, these phosphonates were designed to be resistant to degradation by LPPs. Indeed, the α-monofluoromethylene analogue was more stable than 1-oleoyl-LPA when co-incubated with cultured cells. Thus the potency of the α-monofluoromethylene analogue could be in part attributable to its metabolic stability, but this was not an issue in the calcium release assay employed. We showed that the α-monofluoromethylene analogue was a potent agonist for LPA 3 but not for LPA 1 and LPA 2 , again suggesting that the differential activity at LPA 3 was not due to increased stability [8] .
Phosphonate analogues of PA were synthesized in which the bridging oxygen was replaced by an α-monofluoromethylene (-CHF-) or α-difluoromethylene (-CF 2 -) moiety [15] . The α-difluoromethylene PA analogue [XY-14; 1,1-difluoro-(3S)-3,4-bis-(oleoyloxy)butylphosphonate] produced a marked inhibition of activity of each of the LPPs (LPP1-LPP3) at all concentrations tested. In this case, inhibition was more pronounced at lower LPA concentrations suggesting a competitive mode of inhibition. This difluoromethylene PA analogue was a potent competitive inhibitor of LPP1 activity, potentiated platelet aggregation and shape change responses to LPA and amplified LPA production by agonist-simulated platelets [16] . Moreover, since PA activates signalling in the mTOR (mammalian target of rapamycin) pathway, these metabolically stabilized PA analogues were evaluated in quiescent HEK-293 cells. All analogues surpassed PA in activating S6 kinase. The unnatural (2R) analogues were more active than the unnatural (2S) enantiomers for both the mono-and di-fluoromethylene phosphonates [17] .
Most 
O-alkyl analogues and phosphorothioate analogues
The metabolically stabilized LPA analogue OMPT (1-oleoyl-2-O-methyl-rac-glycerophosphothioate) was described as a potent agonist for the seven transmembrane domain Gprotein-coupled LPA 3 receptors. A new synthetic route for the enantiospecific total synthesis of both (2R)-and (2S)-OMPT provided an efficient route to a variety of O-methylated LPA analogues [18] . The OMPT enantiomers were evaluated in a number of cell-based assays. First, calcium release in both the LPA 3 -transfected insect Sf9 and rat hepatoma Rh7777 cells showed that (2S)-OMPT was 5-20-fold more active than the (2R) enantiomer. Similar results were found for calcium release, MAPK and Akt activation and for IL-6 (interleukin-6) release when measured in human OVCAR3 ovarian cancer cell lines. The results corroborated the known isoform selectivity of OMPT for the LPA 3 [edg-7 (endothelial differentiation gene-7)] relative to the LPA 2 (edg-4) receptor, and established the existence of an enantioselective response to the (2S)-OMPT enantiomer with the unnatural C-2 absolute configuration [18] .
We have also developed an improved and more convenient synthesis of alkyl LPA analogues. The alkyl LPAs induced cell migration with the same potency as natural oleoyl LPA, but this response was not enantioselective. An important finding is that the enantiomeric alkyl LPAs were potent agonists for all three LPA receptor isoforms. In contrast, the alkyl LPA fluoromethylene phosphonates proved to be less potent agonists in this assay [10] . 
Cyclic carba-LPA analogues
The sn-1,2-cyclic phosphate derivative of LPA, commonly known by the misnomer 'cPA (cyclic PA)' affects numerous cellular functions, including anti-mitogenic regulation of the cell cycle, regulation of actin stress fibre formation and rearrangement [20] and inhibition of cancer cells' invasion and metastasis [21] . Recently, ccPAs (carbacyclic analogues of cPA) were found to inhibit metastasis [22] . To explore the SAR of the ccPA compounds, we developed efficient routes to the phosphonothioate and fluoromethylene phosphonate analogues of ccPA (Y. Xu, R. Tsukahara, G. Tigyi and G.D. Prestwich, unpublished work). The pharmacological properties of the ccPAs showed subtype-specific agonist and antagonist activities using Ca 2+ -mobilization assays in Rh7777 cells expressing LPA 1−3 . In particular, the phosphonothioate ccPAs inhibited Ca 2+ release through LPA 1/2 activation, thus showing the properties of selective LPA 1/3 antagonists. The monofluoromethylene phosphonate ccPA was also a potent LPA 1/3 antagonist. In contrast, the difluoromethylene phosphonate ccPA and ccPA itself were weak LPA agonists (Y. Xu, R. Tsukahara, G. Tigyi and G.D. Prestwich, unpublished work). In a separate collaboration (Y. Xu, G.D. Prestwich and E. Honoré, unpublished work), we investigated the activity of the ccPAs by opening the intracellular mechano-gated K2P channel TREK-1 (transmembrane calcium channel-1) [23] . All three analoguesccPA, phosphonothioate ccPA and a monofluoromethylene phosphonate analogue of LPA -opened channels in patched neuronal cell membranes.
LBPA (lysobisphosphatidic acid) and O-alkyl bisether analogues
LBPAs are the major phospholipids of late endosomes (∼15 mol%) and regulate vesicular trafficking, lysosome biogenesis, cell growth and angiogenesis. LBPA has also been shown to be an antigen in the anti-phospholipid syndrome, which can lead to changes in the endosomal sorting and multivesicular endosome formation [24] . The naturally occurring LBPA has a peculiar structure -two acyl chains at each of the sn-2 positions of glycerol backbones. However, this (S,S)-sn-2,2 acyl structure is very labile, and the current synthesis provides only minimal materials for biological studies [25] . We recently developed an improved method of synthesis that provides multimilligram quantities of analogues without acyl migration (G. Jiang, Y. Xu and G.D. Prestwich, unpublished work).
In addition, we developed a versatile, efficient method for the preparation of diethyl ether analogues of (S,S)-LBPA and its enantiomer from (S)-solketal. By simply changing the sequence of deprotection steps, the (R,R)-and (S,S)-enantiomers of 2,2 -bisether LBPA were obtained. An ELISA with anti-LBPA monoclonal antibodies showed that the bisether LBPAs were recognized with the same affinity as the natural 2,2 -bisoleolyl LBPA (G. Jiang, Y. Xu, T. Falguieres, J. Gruenberg and G.D. Prestwich, unpublished work).
Neutral trifluoromethylsulphonamide and trifluorosulphamidoxy analogues
Lipid phosphate esters such as LPA and PA are susceptible to hydrolysis by general and specific phosphatases. In particular, the LPPs mediate cell signalling by changing the ratio between phosphate esters and their dephosphorylated products. The LPPs (as integral membrane proteins) act both inside and outside the cell. One new strategy to produce LPA analogues that can resist LPP hydrolysis depends on substitution of the sn-3 phosphate head group with neutral head groups. The synthesis and biological activity of the first of these, the trifluoromethanesulphonamide group (J. Gajewiak and G.D. Prestwich, unpublished work), have been explored. The LPA trifluoromethanesulphonamide analogue is completely devoid of LPA receptor agonist or antagonist activities, and the activities of the LPA and PA trifluoromethanesulphonamides as inhibitors of LPP activities will be described in due course.
Summary
The chemical synthesis and SARs of metabolically stabilized LPA analogues (Figure 3 ) have revealed novel isoformselective agonists and antagonists for the LPA GPCRs and nuclear receptors. These LPA-selective analogues may well prove to be useful new reagents to characterize cellular and physiological roles of LPA receptor subtypes both in vitro and in vivo. These tools will thus facilitate the unravelling of the fundamental biology of LPA receptor signalling and the development of human therapies based upon targeting these receptors.
